Weight Loss Peptides

Weight Loss Peptides: A Research Overview

GLP-1 receptor agonists represent one of the most significant advances in metabolic research. These peptides mimic the incretin hormone glucagon-like peptide-1, which plays a crucial role in glucose homeostasis and appetite regulation.

Mechanism of Action

GLP-1 receptor agonists work by binding to GLP-1 receptors in the pancreas and brain. In the pancreas, they stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. In the hypothalamus, they activate satiety centers, reducing appetite and food intake.

Key Peptides in This Category

Semaglutide (GLP-1 S) Semaglutide is a synthetic GLP-1 analog with a C18 fatty diacid side chain that enables albumin binding, extending its half-life significantly. Research has demonstrated its efficacy in reducing body weight by 15-17% in clinical trials (STEP trials). It acts primarily through GLP-1 receptor activation.

Tirzepatide (GLP-2 T) Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind. By activating both incretin receptors, it produces enhanced metabolic effects compared to selective GLP-1 agonists alone. The SURMOUNT clinical trials demonstrated weight reductions of up to 22.5% from baseline. Its 39-amino acid structure includes a C20 fatty diacid modification for extended duration of action.

Retatrutide (GLP-3 R) Retatrutide is a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This novel triple-agonist approach addresses multiple metabolic pathways. Phase 2 trial data showed unprecedented weight loss of up to 24% at 48 weeks. The glucagon receptor component may provide additional benefits through increased energy expenditure and hepatic lipid metabolism.

Research Applications

• Metabolic syndrome studies
• Appetite regulation mechanisms
• Glucose homeostasis research
• Body composition analysis
• Cardiovascular outcome studies

Comparative Analysis